In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys

Tolulope A. Aweda1 · Shih-Hsun Cheng1 · Stephen C. Lenhard1 · Armin Sepp2 · Tinamarie Skedzielewski1 · Chih-Yang Hsu1 · Shelly Marshall2 · Heather Haag3 · Jonathan Kehler4 · Prabhas Jagdale3 · Alessia Peter6 · Michael A. Schmid6 · Andrew Gehman7 · Minh Doan1 · Andrew P. Mayer4 · Peter Gorycki5 · Marie Fanget8 · Christophe Colas9 · Brenda Smith10 · Curtis C. Maier11 · Hasan Alsaid

Received: 6 July 2022 / Accepted: 16 October 2022 / Published online: 28 October 2022
© The Author(s) 2022

Abstract
Purpose Sotrovimab (VIR-7831), a human IgG1κ monoclonal antibody (mAb), binds to a conserved epitope on the SARS-CoV-2 spike protein receptor binding domain (RBD). The Fc region of VIR-7831 contains an LS modification to promote neonatal Fc receptor (FcRn)–mediated recycling and extend its serum half-life. Here, we aimed to evaluate the impact of the LS modification on tissue biodistribution, by comparing VIR-7831 to its non-LS-modified equivalent, VIR-7831-WT, in cynomolgus monkeys.

Methods 89Zr-based PET/CT imaging of VIR-7831 and VIR-7831-WT was performed up to 14 days post injection. All major organs were analyzed for absolute concentration as well as tissue:blood ratios, with the focus on the respiratory tract, and a physiologically based pharmacokinetics (PBPK) model was used to evaluate the tissue biodistribution kinetics. Radiomics features were also extracted from the PET images and SUV values.

Results SUVmean uptake in the pulmonary bronchi for 89Zr-VIR-7831 was statistically higher than for 89Zr-VIR-7831-WT at days 6 (3.43 ± 0.55 and 2.59 ± 0.38, respectively) and 10 (2.66 ± 0.32 and 2.15 ± 0.18, respectively), while the reverse was observed in the liver at days 6 (5.14 ± 0.80 and 8.63 ± 0.89, respectively), 10 (4.52 ± 0.59 and 7.73 ± 0.66, respectively), and 14 (4.95 ± 0.65 and 7.94 ± 0.54, respectively). Though the calculated terminal half-life was 21.3 ± 3.0 days for VIR-7831 and 16.5 ± 1.1 days for VIR-7831-WT, no consistent differences were observed in the tissue:blood ratios between the antibodies except in the liver. While the lung:blood SUVmean uptake ratio for both mAbs was 0.25 on day 3, the PBPK model predicted the total lung tissue and the interstitial space to serum ratio to be 0.31 and 0.55, respectively. Radiomics analysis showed VIR-7831 had mean-centralized PET SUV distribution in the lung and liver, indicating more uniform uptake than VIR-7831-WT.

Conclusion The half-life extended VIR-7831 remained in circulation longer than VIR-7831-WT, consistent with enhanced FcRn binding, while the tissue:blood concentration ratios in most tissues for both drugs remained statistically indistinguishable throughout the course of the experiment. In the bronchial region, a higher concentration of 89Zr-VIR-7831 was detected. The data also allow unparalleled insight into tissue distribution and elimination kinetics of mAbs that can guide future biologic drug discovery efforts, while the residualizing nature of the 89Zr label sheds light on the sites of antibody catabolism.

Keywords SARS-CoV-2 · Sotrovimab · Monoclonal antibody · Respiratory tract · Biodistribution · 89Zr-PET · Physiologically based pharmacokinetics (PBPK) · Radiomics

Introduction

Monoclonal antibody (mAb) serum half-life extension is a strategy that is increasingly employed in next-generation mAb biologics to allow for lower doses or reduced dosing frequency [1]. While the impact of Fc region engineering on plasma clearance is well documented across species, the
consequences for tissue distribution and its time course are largely unknown despite its significance to the tissue-embedded target engagement. It has been shown in several studies that enhanced association of the IgG Fc region to the neonatal Fc receptor (FcRn) can prolong the half-life of the antibody [1–3]. The interaction with FcRn leads to partial recycling of endocytosed IgG by rerouting the antibodies back to the cell surface rather than toward lysosomal degradation [4]. The interaction with FcRn is pH-dependent: endocytosed IgG is trafficked to the cell surface rather than toward lysosomal degradation [5]. A number of modifications on the Fc region have been demonstrated to increase the affinity to FcRn at low pH, thereby modulating the pharmacokinetics of the antibody, increasing serum availability, and prolonging therapeutic effect [1, 6, 7]. One of these Fc variants is the LS modification which comprises of amino acid substitutions (Met428Leu + Asn434Ser), and it was shown to prolong the serum half-lives of antibodies up to 3–5-fold [8].

Sotrovimab (VIR-7831) is an LS-modified human IgG1κ mAb that binds to a highly conserved epitope on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, neutralizing the virus [9]. VIR-7831 is effective for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2 [10]. Previous studies in monkeys with an anti-HIV mAb, VRC01, demonstrated that the LS modification increased half-life and enhanced rectal mucosal tissue localization compared to wild-type VRC01. It also afforded superior protection from rectal simian-HIV infection [11]. Since SARS-CoV-2 is primarily a respiratory virus, it was desirable to understand if the LS modification in VIR-7831 afforded similar advantages for lung biodistribution.

Positron emission tomography and computed tomography (PET/CT) has been extensively used to study the tissue distribution of monoclonal antibodies labeled with zirconium-89 (89Zr) which allows for the full body monitoring of drug distribution in live animals for a long duration post-injection as a result of its 78.42-h half-life [12, 13]. In this study, PET/CT imaging was conducted in cynomolgus monkeys to determine the potential effects of the LS modification on biodistribution of VIR-7831 in all major organs, with special focus on the upper and lower respiratory tract. Drug concentrations in blood, tissues, and PET data were modeled by physiologically based pharmacokinetics (PBPK) to evaluate the tissue distribution kinetics of VIR-7831 and the non-LS-modified wild-type VIR-7831-WT antibodies.

To further investigate differences between the groups, radiomics analysis was conducted [14], involving the extraction and selection of high-dimensional quantitative image features such as intensity profiles, shapes, and textures. Additionally, to analyze the spatial distribution of 89Zr-labeled mAb with proximity to blood supply, the lung was further separated into three regions using levelset analysis based on the distance to blood supply.

Materials and methods

Radiolabeling and binding activity of 89Zr-labeled mAbs

VIR-7831 and VIR-7831-WT (GSK) were modified with p-SCN-Bn-deferoxamine (DFO) (Macrocylics) at an input antibody to chelate molar ratio of 1:1; then, 89Zr was complexed with the obtained DFO-labeled mAb at a ratio of 111 MBq/mg of mAb. The stability of 89Zr-mAbs was tested by incubation in 10% monkey serum and in PBS at 37 °C for up to 7 days.

The binding affinities of VIR-7831 and VIR-7831-WT for the human FcRn and the SARS-CoV-2 spike protein receptor binding domain (RBD) were determined by ELISA (enzyme-linked immunosorbent assay) before and after radiolabeling to confirm that the radiolabeling procedure with 89Zr did not affect the functionality of these antibodies (see the Supplemental Materials).

Experimental design and PET/CT imaging

Minimally sufficient group sizes of \( n = 3 \) naïve female cynomolgus monkeys (3.5–5.5 years old) from Envigo, USA, were used in this study. Paired animals were assigned to the different groups based on body weight. The study was conducted in accordance with the GSK Policy on the Care, Welfare, and Treatment of Laboratory Animals and was reviewed by the Institutional Animal Care and Use Committee at GSK. Each monkey had an intravenous catheter placed in either the tail vein or saphenous vein for injection of 1 mg (~92.5 MBq, 2.5 mCi) radiolabeled mAb mixed with unlabeled mAb for a total dose of 5 mg/kg in approximately 10 mL total volume (Supplemental Table S1). In this study, the 5 mg/kg dose replicates what was used in previous pharmacokinetic studies in this species and represents a lower exposure than observed clinically at 500 mg, a dose that was demonstrated to provide protective exposures against susceptible variants in the lung for up to 28 days [10]. The dose was administered by IV slow bolus injection over 5 min on day 0. PET/CT acquisition was performed on days 1, 3, 6, 10, and 14 using a Mediso MultiScan LFER150 system. Details are in the Supplemental Material.

Quantitative standardized uptake value (SUV\(_{\text{mean}}\)) of 89Zr-mAb was measured using VivoQuant software v.3.5 (InviCRO) in the organs and tissues of interest (brain, nasal cavity, pharynx, larynx, trachea, pulmonary bronchi, total...
lungs including “air space,” liver, myocardium, “left ventricular, LV,” blood in left ventricular, spleen, renal cortex, renal medulla, small intestine, large intestine, bladder, axillary lymph node, and muscle). $^{89}$Zr-mAb uptake in the lung tissue (excluding air space) was calculated using a correction factor of 2.81 [15]. Data are reported as group mean ± SEM (standard error of mean).

**Drug concentration in tissues, blood, and serum from imaging**

Absolute molar concentrations of $^{89}$Zr-labeled VIR-7831 and VIR-7831-WT in organs of interest were calculated using the specific activity $a$ (Bq/mole) of the dose as given to each animal (Supplemental Material) [16].

Ex vivo blood radioactivity was measured on samples collected before each imaging session by gamma counting using a Wizard 2480 Gamma Counter (PerkinElmer) and corrected for $^{89}$Zr decay. The serum concentration was calculated from the blood concentration using a monkey hematocrit correction factor of 0.38 [16]. Total serum concentrations (both labeled and unlabeled antibody) were measured by Gyrolab immunoassay for all animals up to day 14, which was extended for animals # 3–6 up to week 8.

**Statistical analysis**

The statistical analysis software SAS (version 9.4 TS Level 1 M) was used to model the PET SUV$_\text{mean}$ and PET tissue: blood ratio data values and to perform statistical tests of mAb group differences at a 0.05 level of significance.

Terminal half-lives for VIR-7831-WT and VIR-7831 were calculated from the day 6 to week 8 serum immunoassay data with a single-exponential decay model by non-linear regression in Matlab 2019a/SimBiology v5.8.4 (MathWorks).

Quantitative tissue distribution of VIR-7831 and VIR-7831-WT was analyzed in terms of absolute concentrations within the framework of cross-species/cross-modality PBPK as described previously [13, 17]. Details are in the Supplemental Material.

**Advanced image analysis**

Radiomics feature analysis was used to distinguish image patterns between the different groups to derive more insights into the PET distribution [14, 18]. Levelset analysis of the lung using scikit-fmm [19] was performed to investigate SUV distribution with proximity to major blood supply. Details are in the Supplemental Material.

**Results**

**Quality and functionality of $^{89}$Zr mAbs**

DFO-VIR-7831 and DFO-VIR-7831-WT antibody conjugates were successfully prepared and purity was confirmed by SEC HPLC. Radiolabeling yield for the $^{89}$Zr-DFO antibodies before purification through a size exclusion cartridge was $84 \pm 3\%$, while $\geq 95\%$ radiochemical purity was achieved after SEC purification as confirmed by analytical HPLC. Molar activities (specific activity) of $15.9 \pm 1.2$ MBq/nmol (2.87 ± 0.2 mCi/mg) and $13.1 \pm 1.1$ MBq/nmol (2.36 ± 0.2 mCi/mg) were achieved for $^{89}$Zr-VIR-7831 and $^{89}$Zr-VIR-7831-WT, respectively. Both $^{89}$Zr-labeled antibody conjugates showed good stability in both buffer and 10% monkey serum with less than 15% loss of $^{89}$Zr after 7 days (Supplemental Fig. S1).

The FcRn binding curve (Fig. 1a) showed stronger binding of FcRn with VIR-7831 than with VIR-7831-WT at pH = 6. Furthermore, the FcRn binding curves obtained with the radiolabeled antibodies ($^{89}$Zr-VIR-7831 and $^{89}$Zr-VIR-7831-WT) overlapped with the ones for the non-radiolabeled VIR-7831 and VIR-7831-WT, respectively. This shows no changes in FcRn binding after radiolabeling with $^{89}$Zr. The binding curve of the antibodies to the RBD (Fig. 1b) showed excellent overlap between VIR-7831 and VIR-7831-WT antibodies. Furthermore, the curves obtained with the radiolabeled antibodies ($^{89}$Zr-VIR-7831 and $^{89}$Zr-VIR-7831-WT) overlapped with the ones for the non-radiolabeled VIR-7831 and VIR-7831-WT, respectively. This shows that the radiolabeling had no effect on the RBD binding of both antibodies.
In vivo PET biodistribution and quantification of \(^{89}\text{Zr}\)-mAbs

Figure 2 shows representative PET/CT images of cynomolgus monkeys on days 3 and 14 post-injection with either VIR-7831 or VIR-7831-WT. The images show higher uptake of \(^{89}\text{Zr}\)-VIR-7831-WT in the liver compared to \(^{89}\text{Zr}\)-VIR-7831 on day 3 and day 14, and a higher blood uptake in the heart for \(^{89}\text{Zr}\)-VIR-7831 compared to \(^{89}\text{Zr}\)-VIR-7831-WT on day 14. The quantitative group mean uptake (SUV\(_{\text{mean}}\)) data of \(^{89}\text{Zr}\)-VIR-7831 and \(^{89}\text{Zr}\)-VIR-7831-WT for all tissues and at all time points are shown in Fig. 3 and Fig. 4, respectively. A summary of the mean uptake (SUV\(_{\text{mean}}\)) for tissues showing statistical differences between antibodies is shown in Table 1. The SUV\(_{\text{mean}}\) after day 1 was trending higher in the blood (left ventricular) in the VIR-7831-treated group compared to the VIR-7831-WT with statistical significance achieved on day 10 (5.81 ± 0.69 and 4.84 ± 0.29, respectively; \(p = 0.0375\)). There was a trend of higher group mean \(^{89}\text{Zr}\)-VIR-7831 uptake in the pulmonary bronchi compared to \(^{89}\text{Zr}\)-VIR-7831-WT uptake beginning on day 3 that achieved statistical significance on day 6 (3.43 ± 0.55 and 2.59 ± 0.38, respectively) and on day 10 (2.66 ± 0.32 and 2.15 ± 0.18, respectively). Also, \(^{89}\text{Zr}\)-VIR-7831 uptake in the liver compared to \(^{89}\text{Zr}\)-VIR-7831-WT uptake was statistically lower on day 6 (5.14 ± 0.80 and 8.63 ± 0.89, respectively), on day 10 (4.52 ± 0.59 and 7.73 ± 0.66, respectively), and on day 14 (4.95 ± 0.65 and 7.94 ± 0.54, respectively). No other noteworthy differences between \(^{89}\text{Zr}\)-VIR-7831 uptake and \(^{89}\text{Zr}\)-VIR-7831-WT uptake were detected in the examined tissues.

The tissue:blood SUV\(_{\text{mean}}\) ratios calculated for \(^{89}\text{Zr}\)-VIR-7831 and \(^{89}\text{Zr}\)-VIR-7831-WT increased with time during the 2-week imaging study, as shown in Supplemental Fig. S2 and Fig. S3. Tissue:blood ratios in the liver were significantly lower for \(^{89}\text{Zr}\)-VIR-7831 than for \(^{89}\text{Zr}\)-VIR-7831-WT at all time points. While there were occasional statistically significant differences in tissue:blood ratios observed in other tissues, these findings were considered sporadic because they were not consistent over time or in directionality.

On day 3, which is expected to roughly correspond to the end of the antibody distribution phase [20], the \(^{89}\text{Zr}\)-VIR-7831 group mean tissue:blood ratio in the pulmonary bronchi (0.41) was higher than in other respiratory tract tissues, including the nasal cavity (0.29), pharynx (0.20), larynx (0.23), trachea (0.16), and total lung (0.25, including air space). \(^{89}\text{Zr}\)-VIR-7831 tissue:blood ratio in the lung tissue excluding air space was 0.70.

Serum drug concentration

Drug concentration profiles derived from the analysis of the labeled fraction of the dosed mAb from the left ventricular PET and the ex vivo gamma counting showed very good agreement with the data from the Gyrolab immunoassay of VIR-7831 and VIR-7831-WT measuring total antibody concentrations as shown on Fig. 5a. The calculated terminal half-life is 21.3 ± 3.0 days for VIR-7831 and 16.5 ± 1.1 days.
for VIR-7831-WT. The fitted data are shown on Fig. 5b. Serum concentration data from animal #4 receiving VIR-7831-WT demonstrated increasing deviation from linearity over the last three data points (from 42 days onward). Therefore, full time course immunoassay data was available only for one VIR-7831-WT-treated animal (#6) and two VIR-7831-treated animals (#3 and #5) after 42 days.

**Tissue concentrations based on PBPK modeling**

Further quantitative mechanistic insight into VIR-7831-WT and VIR-7831 tissue distribution was sought by PBPK to model the tissue penetration kinetics of VIR-7831-WT and VIR-7831 mAbs and the contribution of $^{89}$Zr residualization from catabolized mAbs to the overall detected signal. The default physiological system parameters [13] provided satisfactory fitting to the SUV measurements for the lungs, skeletal muscle, spleen, brain, lymph nodes, and gastrointestinal tract with no parameter adjustment, as shown on Fig. 6. The PBPK model predicted higher concentrations of VIR-7831 vs VIR-7831-WT in the total lung tissue, the interstitial space, and the alveolar epithelial lining fluid (125 nM vs 109 nM, 219 nM vs 188 nM, 8 nM vs 7 nM on day 3, respectively) (Supplemental Table S2). However, tissue:serum ratios were similar up to day 14 (0.31, 0.55, and 0.02 on day 3, respectively) (Supplemental Table S3). In the case of the kidneys and liver, the observed signal was stable in time and substantially exceeded the default PBPK model prediction and therefore, additional modeling was performed. The kidney signal matched the model if it was assumed that 1.1% of the injected $^{89}$Zr was not bound to the mAb. For the liver, satisfactory agreement between the data and the model was achieved by non-linear least squares optimization of the amount of the dose that was irreversibly captured in the organ during the first 24 h post-dosing.

**Predictive radiomics features and levelset analysis**

Radiomics analysis detected differences only in the lung and liver and no other ROI. Skewness of the PET intensity histogram inside the lungs was significantly different between antibodies using the linear mixed effect model ($p < 0.05$) between the two groups at days 6, 10, and 14. The VIR-7831-WT group had a longer right tail compared to the VIR-7831 group as shown in Fig. 7a. Skewness measures tail length of the intensity histogram with positive values...
indicating right tail and negative values indicating left tail. Also, kurtosis of the PET intensity histogram inside the lungs was significantly different ($p < 0.05$) between the two groups at days 6, 10, and 14. Kurtosis measures the spread of the intensity histogram, with high values indicating toward the tails and low values indicating toward the mean. The VIR-7831-WT group had higher kurtosis with distribution more toward the tails while the VIR-7831 group was more centralized toward the mean as shown in Fig. 7b.

Combining both features, VIR-7831 had more voxels with PET intensity similar to the mean indicating more uniform uptake. Similar observation can be seen in the liver with interquartile range; VIR-7831 consistently had lower interquartile range with significant difference at all time points implying more uniform uptake as shown in Fig. 7c. Interquartile range measures the difference between the 75 and 25 percentiles of the intensity histogram. Larger numbers indicate wider spread while smaller numbers indicate more centralized distribution.

The 3D levelset analysis of the lung shown in Fig. 8 displays the average of $\text{SUV}_{\text{mean}}$ in the three distance groups across all time points. The VIR-7831 group had statistically higher uptake in the region closest to the bronchi on day 6.

**Table 1** Summary table for average of $\text{SUV}_{\text{mean}}$ in tissues with $p$ values between VIR-7831 and VIR-7831-WT groups. Significant statistical differences at $p < 0.05$

| Organ              | Day post-injection | VIR-7831 $\text{SUV}_{\text{mean}}$ | VIR-7831-WT $\text{SUV}_{\text{mean}}$ | $p$ value |
|--------------------|-------------------|-------------------------------------|----------------------------------------|-----------|
| Blood (LV)         | 1                 | 12.98                               | 14.45                                  | 0.3674    |
|                    | 3                 | 10.03                               | 9.07                                   | 0.1817    |
|                    | 6                 | 7.61                                | 6.70                                   | 0.0720    |
|                    | 10                | 5.81                                | 4.84                                   | 0.0375    |
|                    | 14                | 4.92                                | 4.23                                   | 0.0668    |
| Pulmonary bronchi  | 1                 | 4.75                                | 4.80                                   | 0.8917    |
|                    | 3                 | 4.13                                | 3.43                                   | 0.0523    |
|                    | 6                 | 3.43                                | 2.59                                   | 0.0080    |
|                    | 10                | 2.66                                | 2.15                                   | 0.0262    |
|                    | 14                | 2.35                                | 2.07                                   | 0.0609    |
| Liver              | 1                 | 6.36                                | 8.47                                   | 0.1001    |
|                    | 3                 | 5.57                                | 7.60                                   | 0.0715    |
|                    | 6                 | 5.13                                | 8.63                                   | 0.0233    |
|                    | 10                | 4.52                                | 7.73                                   | 0.0218    |
|                    | 14                | 4.95                                | 7.94                                   | 0.0293    |
and reduced to similar levels as VIR-7831-WT on days 10 and 14. The VIR-7831 group tended to decay slower compared to the VIR-7831-WT group.

Discussion

This study utilized PET imaging to evaluate tissue distribution of a radiolabeled LS-modified anti-SARS-CoV-2 IgG1 mAb compared to that of its wild-type counterpart. This publication presents the quantitative and mechanistic insights into tissue distribution and catabolism of biologics that can be obtained from PET/CT imaging. The LS modification comprises amino acid substitutions known to enhance affinity of the antibody for the human FcRn [8]. We verified that the stronger binding of VIR-7831 for the human FcRn at acidic pH was not affected by the $^{89}\text{Zr}$ labeling procedure. This potentially translated to longer half-life exhibited by VIR-7831 as compared to VIR-7831-WT ($21.3 \pm 3.0$ days vs $16.5 \pm 1.1$ days, respectively). However, FcRn-binding affinity is not the sole factor that determines the half-life of antibodies even in the absence of target-mediated clearance since the impact from the Fab regions can also have an effect though previously insufficiently understood [21]. The terminal 16.5-day half-life of VIR-7831-WT is more than double of that of typical human mAbs in monkeys ($\approx 7.5$ days) [20], while the 21.3-day half-life of VIR-7831 is similar to that of an half-life extended anti-VEGF mAb (albeit one carrying different set of Fc mutations) [22]. Overall, antibody half-life correlation from FcRn affinity is moderate, implying dependence on other factors [23]. Therefore, the modest half-life extension of VIR-7831 in monkeys primarily reflects atypically and unexpectedly long half-life of the parent wild-type for which we have no mechanistic explanation, while that of VIR-7831 is in the range expected for half-life extended variant mAbs.

The total lung: blood ratio for VIR-7831 antibody on day 3 (0.25) is within the range of values reported elsewhere, e.g., 0.25 and 0.68 [24, 25], which corroborates the value used in clinical dose projections [10]. The PBPK model predicted greater interstitial space: serum ratio (0.55) compared to total predicted lung tissue: serum ratio (0.31) which is related to the antibodies mostly confined to the extracellular space. This predicted interstitial space: serum ratio is also higher than the alveolar epithelial lining fluid: serum ratio (0.02) which reflects the experimentally observed concentration gradient between alveolar epithelial lining fluid (ELF) and serum. The modeled higher interstitial: serum ratio compared to whole lung: serum is consistent with observations from Eigenmann et al. [26].

![PET or Ex Vivo gamma counting](image1)

Fig. 5  Monoclonal antibody, mAb concentration (a) as measured by ex vivo gamma counting (circles) and PET (crosses) vs ELISA for VIR-7831-WT (blue) and VIR-7831 (red). Dotted line: linear proportional prediction. Serum half-life (b) of VIR-7831 (red) and VIR-7831-WT (blue) as measured by Gyrolab immunoassay. Terminal half-life was determined from days 6 to 56 data.
VIR-7831 has no binding activity except to the spike protein; hence, its tissue distribution and elimination kinetics in uninfected monkeys can be interpreted as being unbiased by its antigen-binding properties, making it an excellent case study in biodistribution of antibodies. As a result, the insight gained can also be useful for mAbs directed against other targets; through physiologically based pharmacokinetic models, we can capture the biodistribution of mAbs in target tissues while adding the expression of membrane bound or soluble targets to capture any TMDD happening in the system. This can be extrapolated to biologics modalities beyond antibodies and could be a useful tool for dose prediction for humans. The same physiologically based pharmacokinetic framework has been shown to describe the tissue distribution and elimination kinetics of a variety of biological modalities in mice, rats, monkeys, and humans [13], covering the essential species repertoire relevant to the global drug discovery efforts. As such, the framework is not necessarily limited to therapeutic modalities but is expected to be applicable to all soluble proteins, endogenous or dosed [17].

The agreement between the three methods used to measure serum concentrations validated the use of PBPK with PET/CT data as the model accommodates both WT mAb and FcRn affinity enhanced mAb. Furthermore, PET measurements are direct, in vivo, minimally invasive, and quantitative, with no need for ex vivo sampling and tissue preparation artifacts. Even though there were generally higher VIR-7831 levels in blood than VIR-7831-WT, similar tissue:blood ratios were observed across tissues between VIR-7831 and VIR-7831-WT with the exception of the liver and the pulmonary bronchi at some time points. As the liver is a primary organ of antibody catabolism, the $^{89}$Zr-labeled antibody undergoing local degradation would be expected to accumulate in this site, while any free $^{89}$Zr in serum would be captured in the kidneys [13] or in the bone depending on its complexed composition, as the oxalate and chloride forms could have significant retention in the bone [27].

The lower VIR-7831 liver $\text{SUV}_{\text{mean}}$ compared to VIR-7831-WT is consistent with FcRn-dependent mAb recycling that is expected to rescue VIR-7831 from lysosomal degradation [8]. This is also supported by radiomics analysis showing VIR-7831 with smaller interquartile range in the liver, indicating the signal was more uniform for VIR-7831 relative to a more punctate signal for VIR-7831-WT. While brain and skeletal muscle displayed relatively low and constant signal, peripheral blood and highly perfused tissues such as the digestive tract, lungs, and bronchi reached high levels after dosing before decaying over time. Within separate sections of respiratory tract, the highest initial signal was detected in the bronchial and nasal regions which are among the most vascularized tissues [28].

The $\text{SUV}_{\text{mean}}$ in the pulmonary bronchi tended to be higher in both groups compared to that in other tissues in the respiratory tract and uptake was significantly higher in the VIR-7831-treated group compared to that in the VIR-7831-WT-treated group at days 6 and 10. This finding appears to be specific to pulmonary bronchi rather than a general phenomenon of higher VIR-7831 blood concentrations because other highly vascularized tissues in the respiratory tract, such as the whole lung, showed no differences in group mean uptake between mAbs. The tissue:blood ratio reflects the fraction of mAb content in the capillaries, cells, and interstitial spaces of an organ relative to that in blood. In the case of the lungs, this also includes alveolar ELF, which is directly accessible as bronchial alveolar lavage (BAL). In the case of anti-respiratory syncytial virus (RSV) monoclonal antibody (MEDI-524), it was found that both wild-type and half-life extended versions of the mAb displayed statistically indistinguishable BAL:plasma partition, suggesting that higher FcRn-binding affinity of the mAb primarily enhances ELF exposure through elevated plasma concentration and the two compartments are in connection through predominantly passive paracellular exchange [7, 29]. Interestingly, for several organs, the ratio continued to increase even well beyond the mAb distribution phase, suggesting the impact of residualization given that no residualizing signal is expected in the blood. On day 3, the VIR-7831 group mean tissue:blood ratio in the pulmonary bronchi and lung tissue excluding air space was higher than in other respiratory tract tissues. In addition, the 3D levelset analysis showed significantly higher uptake of VIR-7831 compared to VIR-7831-WT in the lung region most proximal to the pulmonary bronchi. This may suggest that higher blood concentrations for VIR-7831 also result in proportionately higher interstitial concentrations in this lung region as the overall tissue:blood ratio is independent of half-life for mAbs [7, 30]. This was confirmed by the PBPK modeling predicting higher concentrations of VIR-7831 in the lung interstitial space and the alveolar epithelial lining fluid which are important with regard to a mAb neutralizing viral entry into cells, and prevent initial infection of epithelial cells, or interstitial cell–cell spread of virus. The higher interstitial concentration was also observed by radiomics with VIR-7831 exhibiting mean-centralized distribution indicating uniform concentration between lung and interstitial spaces [31].
Limitations

PET/CT study provides an in vivo longitudinal imaging of the whole animal but as one of the aims was to evaluate alveolar concentration of the antibodies, PET does not have the resolution (only ~750 μm in this study) required for direct measurement of the 100-nm-thick layer of alveolar epithelial lining fluid (ELF). Other methods as reported elsewhere [26, 30] are based on ex vivo data where tissue samples are excised and blotted to remove surface blood. The samples are typically small, a few hundred milligrams, and some of the tissue blood is simply lost during sample preparation.

In combination with the PET data, the PBPK modeling provides a much more mechanistic and comprehensive model as compared to others. The model is based off 2-pore hypothesis and the parameters for these were fitted using IgG, albumin, and small domain protein. As a result, the model might not be well calibrated for protein in the size range of 50–100 kDa. In addition, the model used here consists of single endosomal compartment for FcRn interactions, thus not taking into account endosomal transit times, or different affinities as pH acidifies from early endosomes to sorting endosomes.

Conclusion

In conclusion, the biodistribution of VIR-7831 compared to VIR-7831-WT was studied in monkeys and imaged by PET/CT up to day 14 after dosing. 89Zr-VIR-7831 had higher uptake in blood and pulmonary bronchi, and lower uptake in the liver, compared to 89Zr-VIR-7831-WT. Higher blood concentrations of VIR-7831 over VIR-7831-WT translated to proportionally higher tissue concentrations. The higher tissue concentrations of the half-life extending LS-modified antibody though only statistically significant in the pulmonary bronchi were found to be in agreement with the level of antibody in circulation, which may guide future biologic drug discovery efforts.

Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s00259-022-06012-3.

Author contribution Conceptualization, and study design: Tolulope A. Aweda, Shih-Hsun Cheng, Christophe Colas, Brenda Smith, Curtis C. Maier, Hasan Alsaid.

Methodology: Tolulope A. Aweda, Shih-Hsun Cheng, Stephen C. Lenhard, Armin Sepp, Tinamarie Skedzielewski, Chih-Yang Hsu, Shelly Marshall, Heather Haag, Jonathan Kehler, Prabhas Jagdale, Alessia Peter, Michael A. Schmid, Andrew Gehman, Minh Doan, Andrew P. Mayer, Peter Gorycki, Marie Fanget, Christophe Colas, Brenda Smith, Curtis C. Maier, Hasan Alsaid.

Fig. 7 Predictive PET intensity features in the lungs and liver that distinguishes the two groups. (a) PET skewness at days 6, 10, and 14 shows significant difference between the two groups VIR-7831 and VIR-7831-WT. (b) PET kurtosis at days 6, 10, and 14 shows significant difference between the two groups. (c) Liver PET intensity interquartile range at all time points significantly distinguishes the two groups. *p < 0.05

Fig. 8 3D levelset analysis with manually chosen distances classified the lung into three groups based on their distance to the bronchi (near, intermediate, far). Average SUV mean within each group were compared over the five time points. Statistical significance between VIR-7831 and VIR-7831-WT was observed at day 6 for the region closest to the bronchi. *p < 0.05
Data acquisition: Tolulope A. Aweda, Shih-Hsun Cheng, Stephen C. Lenhard, Armin Sepp, Timararie Skedzielewski, Chih-Yang Hsu, Shehly Marshali, Heather Haag, Jonathan Kehler, Prabhias Jagdale.

Data analysis: Tolulope A. Aweda, Shih-Hsun Cheng, Stephen C. Lenhard, Armin Sepp, Chih-Yang Hsu, Jonathan Kehler, Prabhias Jagdale, Andrew Gehman.

Drafting the manuscript: Tolulope A. Aweda, Shih-Hsun Cheng, Stephen C. Lenhard, Armin Sepp, Timararie Skedzielewski, Chih-Yang Hsu, Shehly Marshali, Heather Haag, Jonathan Kehler, Prabhias Jagdale, Alessia Peter, Michael A. Schmid, Andrew Gehman, Minh Doan, Andrew P. Mayer, Peter Gorycki, Marie Fanget, Christophe Colas, Brenda Smith, Curtis C. Maier, Hasan Alsaid.

Approving the manuscript: Tolulope A. Aweda, Shih-Hsun Cheng, Stephen C. Lenhard, Armin Sepp, Timararie Skedzielewski, Chih-Yang Hsu, Shehly Marshali, Heather Haag, Jonathan Kehler, Prabhias Jagdale, Alessia Peter, Michael A. Schmid, Andrew Gehman, Minh Doan, Andrew P. Mayer, Peter Gorycki, Marie Fanget, Christophe Colas, Brenda Smith, Curtis C. Maier, Hasan Alsaid.

Funding This work was funded by GSK in collaboration with VIR Biotechnology.

Declarations

Ethical approval The study was conducted in accordance with the GSK Policy on the Care, Welfare, and Treatment of Laboratory Animals and was reviewed by the Institutional Animal Care and Use Committee at GSK.

Conflict of interest Tolulope A. Aweda, Shih-Hsun Cheng, Stephen C. Lenhard, Timararie Skedzielewski, Chih-Yang Hsu, Shehly Marshali, Heather Haag, Jonathan Kehler, Prabhias Jagdale, Alessia Peter, Michael A. Schmid, Andrew Gehman, Minh Doan, Andrew P. Mayer, Peter Gorycki, Curtis C. Maier, and Hasan Alsaid are employees of GSK. Armin Sepp is a former employee of Vir Biotechnology, Inc. Christophe Colas is a former employee of VIR Biotechnology, Inc. Colas is a former employee of Vir Biotechnology, Inc.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ko S, Jo M, Jung ST. Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc engineering. BioDrugs. 2021;35:147–57. https://doi.org/10.1007/s40259-021-00471-0.
2. Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. mAbs. 2011;3(5):422–30. https://doi.org/10.4161/mabs.3.5.16983.
3. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, et al. The MHC class I-like IgG receptor controls perinatal IgG transport IgG homeostasis and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170:3528–33. https://doi.org/10.4049/jimmunol.170.7.3528.
4. Nnane IP, Han C, Jiao Q, Tam SH, Davis HM, Xu Z. Modification of the Fc region of a human anti-oncostatin M monoclonal antibody for higher affinity to FcRn receptor and extension of half-life in cynomolgus monkeys. Basic Clin Pharmacol Toxicol. 2017;121:13–21. https://doi.org/10.1111/bcpt.12761.
5. Borrok MJ, Wu Y, Beyaz N, Yu XQ, Oganseyan V, Dall’Acqua WF, et al. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem. 2015;290:4282–90. https://doi.org/10.1074/jbc.M114.603712.
6. Mackness BC, Jaworski JA, Boudanova E, Park A, Valente D, Mauriac C, et al. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. mAbs. 2019;11:1276–88. https://doi.org/10.1080/19420862.2019.1633883.
7. Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgGs engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281:23514–24. https://doi.org/10.1074/jbc.M604292200.
8. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28:157–9. https://doi.org/10.1038/nbt.1601.
9. Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid MA, Agostini ML, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2021;35:1123. https://doi.org/10.1101/2021.03.09.43607.
10. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941–50. https://doi.org/10.1056/NEJMoA2017934.
11. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014;514:642–5. https://doi.org/10.1038/nature13612.
12. Alsaid H, Skedzielewski T, Rambo MV, Hunsiker K, Hoang B, Fieles W, et al. Non invasive imaging assessment of the biodistribution of GS2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice. PLoS ONE. 2017;12:e0176075. https://doi.org/10.1371/journal.pone.0176075.
13. Sepp A, Bergström M, Davies M. Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zs-labelled albumin-binding domain antibody GS3K128349 in humans. mAbs. 2020;12(1). https://doi.org/10.1080/19420862.2020.1832861.
14. Cook GJR, Azad G, Owczarczyk K, Siddique M, Goh V. Challenges and promises of PET radiomimics. Int J Radiat Oncol Biol Phys. 2018;102(4):1083–9.
15. Lambrou T, Groves AM, Erlandsson K, Scratson N, Endozo R, Win T, et al. The importance of correction for tissue fraction effects in lung PET: preliminary findings. 2011;38:2238–46.
16. Hobb TS, Blue SW, Park BS, Greisel JJ, Conn PM, Pau FK. Measurement of blood volume in adult rhesus macaques (Macaca mulatta) J Am Assoc Lab Anim Sci: JALASL. 2015;54:687–93.
17. Sepp A, Neno-Tetang G, Weber A, Sanderson A, Schon O, Berges A. Computer- assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats. J Pharmacokin Pharmacoc. 2019;46:35–9. https://doi.org/10.1007/s10928-019-09640-9.
18. van Griethuysen JIM, Fedorov A, Parmar C, Hosny A, Anco N, Narayan V, et al. Computational radiomics system to decode the histological signatures of human urothelial carcinoma. Sci Rep. 2017;7:3528. https://doi.org/10.1038/s41598-017-0677.
19. sciikit-fmm 0.0.9 documentation. https://pythonhosted.org/scikit- fmm/. Accessed 05 Jul 2022.
20. Betts A, Keunecke A, van Steeg TJ, van der Graaf PH, Avery LB, Jones H, et al. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. mAbs. 2018;5:751–164. https://doi.org/10.1080/19420862.2018.1462429.

21. Gjolberg TT, Frick R, Mester S, Foss S, Greys A, Hoydahl LS, et al. Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life. Commun Biol. 2022;5:832. https://doi.org/10.1038/s42003-022-03787-x.

22. Ng CM, Fielder PJ, Jin J, Deng R. Mechanism-based competitive binding model to investigate the effect of neonatal Fc receptor binding affinity on the pharmacokinetic of humanized anti-VEGF monoclonal IgG1 antibody in cynomolgus monkey. AAPS J. 2016;18:948–59. https://doi.org/10.1208/s12248-016-9911-4.

23. Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, et al. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos. 2012;40:1545–55. https://doi.org/10.1124/dmd.111.045864.

24. Jadhav SB, Khawroongrueng V, Fueth M, Otteneder MB, Richter W, Derendorf H. Tissue distribution of a therapeutic monoclonal antibody determined by large pore microdialysis. J Pharm Sci. 2017;106:2853–9. https://doi.org/10.1016/j.xphs.2017.03.033.

25. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab’)2, and Fab’ in mice. Can Res. 1986;46:3969–78.

26. Eigenmann MJ, Karliesen TV, Krippendorff BF, Tenstad O, Fronton L, Otteneder MB, et al. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches. J Physiol. 2017;595:7311–30. https://doi.org/10.1113/jp274819.

27. Abou DS, Ku T, Smith-Jones PM. In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol. 2011;38:675–81. https://doi.org/10.1016/j.nucmedbio.2010.12.011.

28. Costa A, Andrade F. 4.4 - Tissue-based in vitro and ex vivo models for pulmonary permeability studies. In: Sarmento B, editor. Concepts and models for drug permeability studies: Woodhead Publishing; 2016. 255–72.

29. Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 2010;12:33–43. https://doi.org/10.1208/s12248-009-9157-5.

30. Chang HP, Kim SJ, Shah DK. Whole-body pharmacokinetics of antibody in mice determined using enzyme-linked immuno-sorbent assay and derivation of tissue interstitial concentrations. J Pharm Sci. 2021;110:446–57. https://doi.org/10.1016/j.xphs.2020.05.025.

31. Mascalchi M, Camiciotto G, Diciotti S. Lung densitometry: why, how and when. J Thorac Dis. 2017;9:3319–45.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Tolulope A. Aweda¹ · Shih-Hsun Cheng¹ · Stephen C. Lenhard¹ · Armin Sepp² · Tinamarie Skedzielewski¹ · Chih-Yang Hsu¹ · Shelly Marshall³ · Heather Haag³ · Jonathan Kehler⁴ · Prabhas Jagdale⁵ · Alessia Peter⁶ · Michael A. Schmidt⁶ · Andrew Gehman⁷ · Minh Doan¹ · Andrew P. Mayer⁴ · Peter Gorycki⁵ · Marie Fanget⁸ · Christophe Colas⁹ · Brenda Smith¹⁰ · Curtis C. Maier¹¹ · Hasan Alsaid¹²

¹ Bioimaging, GSK, 1250 S. Collegeville Rd, Collegeville, PA 19426, USA
² Certara UK Ltd, Sheffield, UK
³ Integrated Biological Platform Sciences, GSK, Collegeville, PA, USA
⁴ Bioanalysis, Immunogenicity & Biomarkers, GSK, Collegeville, PA, USA
⁵ DMPK, GSK, Collegeville, PA, USA
⁶ mAb Engineering & Bioanalytics, Humabs BioMed SA, Vir Biotechnology, Inc, Bellinzona, Switzerland
⁷ Non-Clinical and Translational Statistics, GSK, Collegeville, PA, USA
⁸ Bioanalytical Department, Vir Biotechnology, Inc, San Francisco, CA, USA
⁹ DMPK, Vir Biotechnology, Inc, San Francisco, CA, USA
¹⁰ Toxicology, Vir Biotechnology, Inc, San Francisco, CA, USA
¹¹ Non-Clinical Safety, GSK, Collegeville, PA, USA
¹² Springer